Brand Name Pharmaceutical Manufacturing in the US
Over the past five years, the Brand Name Pharmaceutical Manufacturing industry in the United States experienced several new drug launches, with 42 new active substances (NAS) launched in 2017 alone. According to research by IQVIA, the number of new drug launches in 2017 was more than double the number launched in the prior year, with many new drug launches focusing on rare diseases and oncology. Given increasing price scrutiny and competition from generics, as well as intensifying market competition among brand name producers and rising research and development (R&D) expenses, many manufacturers shifted their strategic focus from blockbuster drugs to more lucrative therapy areas, such as rare diseases and oncology. In addition, many brand name manufacturers expanded their product portfolios to include biologic drugs. Over the five years to 2023, many pharmaceutical manufacturers are expected to drive sales volumes from biologic drugs.
Pharmaceutical manufacturers develop prescription and over-the-counter products that are used to prevent or treat illnesses in humans or animals. Brand name drugs and medication have patent protection. This industry does not include nutritional supplement or cosmetic product manufacturers.
This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook